Skip to main content

Table 1 Demographic and baseline clinical characteristics of patients

From: Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Patient characteristicECOG 2 groupECOG 0–1 groupPb
EP arm (n = 31)PC arm (n = 40)paEP arm (n = 64)PC arm (n = 56)pa
Age  0.746  0.4030.923
  < 65, y23 (74.2%)31 (77.5%) 51 (79.7%)41 (73.2%)  
  ≥ 65, y8 (25.8%)9 (22.5%) 13 (20.3%)15 (26.8%)  
 Median5658.5 5956  
 Range32–7042–70 33–7039–70  
Gender  0.627  0.3820.308
 Male25 (80.6%)34 (85.0%) 55 (85.9%)51 (91.1%)  
 Female6 (19.4%)6 (15.0%) 9 (14.1%)5 (8.9%)  
Weight loss  0.276  0.8780.674
  < 5%17 (54.8%)27 (67.5%) 42 (65.6%)36 (64.3%)  
  ≥ 5%14 (45.2%)13 (32.5%) 22 (34.4%)20 (35.7%)  
Smoking history  0.887  0.6440.457
 Yes22 (71.0%)29 (72.5%) 48 (75.0%)44 (78.6%)  
 No9 (29.0%)11 (27.5%) 16 (25.0%)12 (21.4%)  
Pathology  0.912  0.5000.082
 Squamous23 (74.2%)31 (77.5%) 42 (65.6%)31 (55.4%)  
 Adenocarcinoma6 (19.4%)6 (15.0%) 14 (21.9%)15 (26.8%)  
 Other2 (6.5%)3 (7.5%) 8 (12.5%)10 (17.9%)  
AJCC stage  0.747  0.5660.326
 IIIA6 (19.4%)9 (22.5%) 19 (29.7%)14 (25.0%)  
 IIIB25 (80.6%)31 (77.5%) 45 (70.3%)42 (75.0%)  
Tumor stage  0.612  0.3920.662
 T11 (3.2%)0 (0.0%) 0 (0.0%)0 (0.0%)  
 T219 (61.3%)22 (55.0%) 41 (64.1%)33 (58.9%)  
 T37 (22.6%)13 (32.5%) 17 (26.6%)13 (23.2%)  
 T44 (12.9%)5 (12.5%) 6 (9.4%)10 (17.9%)  
Nodal stage  0.594  0.5640.409
 N29 (29.0%)14 (35.0%) 23 (35.9%)23 (41.1%)  
 N322 (71.0%)26 (65.0%) 41 (64.1%)33 (58.9%)  
Pre-RT pulmonary function
 FEV1 (L)c2.09 (1.08–4.38)1.99 (1.17–2.98)0.6382.23 (1.15–4.05)2.07 (0.84–3.08)0.2660.277
 FEV1 (% predicted) c65.1% (35.6–117.1%)65.5% (42.4–103.6%)0.65670.3% (39.3–110.6%)63.1% (22.3–96.7%)0.1330.607
  1. Abbreviations: EP etoposide/cisplatin, PC paclitaxel/carboplatin, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, FEV1 forced expiratory volume in 1 s
  2. ap value for testing the null hypothesis of no difference between patients receiving EP and PC chemotherapy
  3. bp value for testing the null hypothesis of no difference between ECOG 2 group and ECOG 0–1 group
  4. c Median (range)